{"id":16695,"date":"2023-07-03T13:12:00","date_gmt":"2023-07-03T05:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16695"},"modified":"2024-12-04T13:16:43","modified_gmt":"2024-12-04T05:16:43","slug":"transcentas-osemitamab-combo-shows-promising-pfs-data-in-advanced-gc-gej-cancer-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16695","title":{"rendered":"Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study"},"content":{"rendered":"\n

Transcenta Holding Ltd (HKG: 6628<\/a>), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data based on CLDN18.2 expression levels from a Phase I\/II study of osemitamab (TST001) in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment for advanced gastric\/gastroesophageal junction (GC\/GEJ) carcinoma at the ESMO World Congress on Gastrointestinal Cancer 2023. The positive data supports the initiation of a global Phase III pivotal trial, scheduled for the second half of 2023.<\/p>\n\n\n\n

Phase I\/II Study Results and Efficacy<\/strong>
The efficacy and safety of osemitamab (TST001) plus the chemotherapy regimen (CAPOX) as a first-line treatment for patients with advanced GC\/GEJ cancer were explored in a dose escalation and expansion Phase I\/II study in China (Cohort C of TranStar102, NCT04495296). Among the 49 patients who received a 6mg\/kg dose during the dose extension phase, 42 had measurable lesions and underwent at least one post-treatment tumor evaluation, with 28 patients (66.7%) achieving partial response (PR). As of the April 21, 2023, cut-off date, 26 out of 64 patients had progressive disease or death, resulting in an estimated median PFS of 9.5 months. Notably, there was no clear trend between PFS and CLDN18.2 expression levels.<\/p>\n\n\n\n

Osemitamab (TST001) Profile and Clinical Progress<\/strong>
Osemitamab (TST001) is a high-affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC). The drug is currently under multiple clinical studies in the US and China. It has been granted Orphan Drug Designation from the US FDA for the treatment of patients with GC\/GEJ and pancreatic cancer, highlighting its potential as a valuable therapy for these patient populations.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,17,975,181],"class_list":["post-16695","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-hkg-6628","tag-transcenta"],"yoast_head":"\nTranscenta's Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data based on CLDN18.2 expression levels from a Phase I\/II study of osemitamab (TST001) in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment for advanced gastric\/gastroesophageal junction (GC\/GEJ) carcinoma at the ESMO World Congress on Gastrointestinal Cancer 2023. The positive data supports the initiation of a global Phase III pivotal trial, scheduled for the second half of 2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16695\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transcenta's Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16695\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-03T05:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T05:16:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16695#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16695\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC\\\/GEJ Cancer Study\",\"datePublished\":\"2023-07-03T05:12:00+00:00\",\"dateModified\":\"2024-12-04T05:16:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16695\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial results\",\"HKG: 6628\",\"Transcenta\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16695#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16695\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16695\",\"name\":\"Transcenta's Osemitamab Combo Shows Promising PFS Data in Advanced GC\\\/GEJ Cancer Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-03T05:12:00+00:00\",\"dateModified\":\"2024-12-04T05:16:43+00:00\",\"description\":\"Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data based on CLDN18.2 expression levels from a Phase I\\\/II study of osemitamab (TST001) in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment for advanced gastric\\\/gastroesophageal junction (GC\\\/GEJ) carcinoma at the ESMO World Congress on Gastrointestinal Cancer 2023. The positive data supports the initiation of a global Phase III pivotal trial, scheduled for the second half of 2023.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16695#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16695\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16695#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC\\\/GEJ Cancer Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Transcenta's Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study - Insight, China's Pharmaceutical Industry","description":"Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data based on CLDN18.2 expression levels from a Phase I\/II study of osemitamab (TST001) in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment for advanced gastric\/gastroesophageal junction (GC\/GEJ) carcinoma at the ESMO World Congress on Gastrointestinal Cancer 2023. The positive data supports the initiation of a global Phase III pivotal trial, scheduled for the second half of 2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16695","og_locale":"en_US","og_type":"article","og_title":"Transcenta's Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16695","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-03T05:12:00+00:00","article_modified_time":"2024-12-04T05:16:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16695#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16695"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study","datePublished":"2023-07-03T05:12:00+00:00","dateModified":"2024-12-04T05:16:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16695"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial results","HKG: 6628","Transcenta"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16695#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16695","url":"https:\/\/flcube.com\/?p=16695","name":"Transcenta's Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-03T05:12:00+00:00","dateModified":"2024-12-04T05:16:43+00:00","description":"Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data based on CLDN18.2 expression levels from a Phase I\/II study of osemitamab (TST001) in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment for advanced gastric\/gastroesophageal junction (GC\/GEJ) carcinoma at the ESMO World Congress on Gastrointestinal Cancer 2023. The positive data supports the initiation of a global Phase III pivotal trial, scheduled for the second half of 2023.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16695#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16695"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16695#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC\/GEJ Cancer Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16695"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16695\/revisions"}],"predecessor-version":[{"id":16696,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16695\/revisions\/16696"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}